How to Treat Cirrhosis: From Diet to Transplant

Treating cirrhosis is not a single intervention but a layered strategy that depends on how advanced the scarring is, what caused it, and which complications have appeared. For people in early stages, removing the underlying cause and adjusting daily habits can slow or even partially reverse liver damage. For those with advanced disease, treatment shifts toward managing dangerous complications like fluid buildup, confusion from toxin accumulation, and kidney failure, with liver transplantation as the definitive option when the organ can no longer keep up. The range of available tools has expanded considerably in recent years, and the idea that cirrhosis is always a one-way street toward organ failure is outdated.

Removing the Cause Matters More Than Anything Else

The single most impactful step in treating cirrhosis is addressing whatever is destroying liver cells in the first place. For alcohol-related cirrhosis, that means stopping drinking entirely. A large study tracking patients with alcohol-related cirrhosis who had already developed complications found that about a third achieved what doctors call “recompensation,” meaning their liver stabilized enough to no longer meet criteria for decompensated disease. Among those who recompensated and stayed sober, none died of liver-related causes or developed liver cancer during follow-up.¹ A separate study confirmed that abstinence cut the risk of new decompensation events roughly in half and reduced liver-related death across all severity levels of portal hypertension, even in patients with the highest pressure readings.²

For hepatitis C, antiviral drugs that cure the infection can improve liver function within months.³ There is an important caveat, though: the benefit depends on timing. Patients treated while cirrhosis is still in its early stages and portal pressure is only mildly elevated have the best chance of fibrosis reversal. Those who already have clinically significant portal hypertension often remain at risk for complications even after the virus is gone, because the high pressure does not fully resolve.⁴ This is one reason hepatologists push hard for early screening and treatment: waiting until cirrhosis is advanced narrows what antiviral cure can accomplish.

For hepatitis B, long-term antiviral suppression works on a similar principle, and autoimmune hepatitis responds to immunosuppressive therapy. In a study of cirrhotic patients whose liver inflammation was suppressed over time, roughly one in eight showed biopsy-confirmed reversal of cirrhosis, with fibrosis scores dropping substantially.⁵ The broader takeaway is that fibrosis is not a permanent state. Experimental and clinical evidence both support the idea that when you remove the ongoing injury, the liver can remodel scar tissue, at least to a degree.⁶

A Newer Frontier for Fatty Liver Disease

Metabolic dysfunction-associated steatohepatitis, commonly known as MASH (formerly called NASH), is now one of the fastest-growing causes of cirrhosis worldwide. Until recently, there were no approved drugs targeting the disease itself; treatment was limited to weight loss, diabetes management, and lifestyle changes. Resmetirom, a thyroid hormone receptor agonist, has emerged as the first medication specifically approved for MASH-related fibrosis. In patients who already had compensated cirrhosis from MASH, treatment with resmetirom for up to two years improved liver stiffness measurements, fibrosis biomarkers, and markers associated with portal hypertension risk.⁷ Quality-of-life measures also improved, with reductions in health-related worry and distress that held through the second year of treatment.⁸ This area is still evolving, and resmetirom is not a cure, but it represents the first targeted pharmacotherapy for a cause of cirrhosis that previously had none.

Diet and Nutrition

Malnutrition is surprisingly common in cirrhosis, even in people who are overweight. A scarred liver has trouble storing glycogen and processing nutrients efficiently, so the body enters a starvation-like state overnight much faster than it would in a healthy person. This accelerated breakdown of muscle protein contributes to sarcopenia, a loss of muscle mass and strength that worsens outcomes. One practical countermeasure is a late-evening snack that includes both carbohydrates and protein. The nutritional composition of these snacks matters for preventing the overnight catabolic spiral that drives muscle loss.⁹

For people who have developed ascites (fluid accumulation in the abdomen), sodium restriction is a core part of dietary management. Reducing salt intake to around 80 to 120 millimoles per day helps limit fluid retention, and it works in tandem with diuretic medications.¹⁰ This does not mean a bland, joyless diet; it means learning to cook with herbs and spices instead of salt, avoiding processed foods, and reading nutrition labels carefully. Protein restriction, which was once standard advice in cirrhosis, has largely fallen out of favor. Most guidelines now recommend adequate protein intake, roughly 1.2 to 1.5 grams per kilogram of body weight per day, because the risk of muscle wasting outweighs the theoretical risk of worsening hepatic encephalopathy.

A systematic review comparing different dietary approaches for sarcopenia in cirrhosis found that high-calorie, high-protein diets improved grip strength, a standard measure of muscle function.¹¹ In other words, eating enough is not just about comfort; it directly affects your physical capacity and, by extension, your eligibility and resilience for potential future treatments including transplant.

Exercise Is Safe and Helpful, Even in Advanced Disease

There has been a lingering fear among patients and some clinicians that exercise could be dangerous in cirrhosis, perhaps triggering a variceal bleed or worsening portal pressure. The evidence says otherwise. Programs combining aerobic activity and resistance training at moderate intensity, sustained for at least eight to twelve weeks, improve markers of sarcopenia, cardiovascular fitness, and quality of life. These benefits hold in both compensated and decompensated patients, and the interventions have proven safe whether done in a clinical setting or at home.¹²

One pilot trial even measured portal pressure directly before and after an exercise program. The exercise group saw portal pressure drop, while the control group’s pressure actually rose, with a significant difference between the two groups. No episodes of variceal bleeding or hepatic encephalopathy occurred during the study.¹³ This was a small trial, so the results need to be confirmed in larger studies, but they are enough to challenge the assumption that people with cirrhosis should avoid physical activity. The practical recommendation is moderate-intensity exercise, something like brisk walking, cycling, or light weightlifting, after discussing the specifics with your care team.

Managing Complications as They Arise

As cirrhosis progresses, the complications that develop often drive the treatment plan more than the underlying disease itself. Each major complication has its own management pathway.

Ascites and Diuretics

Fluid retention in the abdomen is one of the earliest signs that cirrhosis has moved into its decompensated phase. First-line treatment combines the dietary sodium restriction described above with diuretic medications. For a first episode of moderate ascites, spironolactone alone is often sufficient, starting at 100 milligrams and increasing as needed. For recurrent or severe ascites, or when the patient is hospitalized and faster fluid removal is needed, spironolactone is combined with furosemide.¹⁴ Doses of both drugs can be increased in a stepwise fashion, but careful monitoring of kidney function and electrolytes is essential because these medications can tip fragile kidneys into trouble.

When ascites no longer responds to maximum-dose diuretics, the condition is called “refractory ascites,” and the options shift. Repeated large-volume paracentesis, essentially draining the fluid with a needle, provides relief but does not address the underlying pressure. A procedure called TIPS, where a radiologist creates a small channel through the liver to reduce portal pressure, is more effective at preventing fluid from reaccumulating. A meta-analysis found that TIPS significantly reduced recurrent ascites and improved transplant-free survival compared to paracentesis alone.¹⁵ The trade-off is a higher rate of hepatic encephalopathy, since diverting blood around the liver means fewer toxins get filtered out.¹⁶

Hepatic Encephalopathy

When the liver cannot adequately clear ammonia and other toxins, they accumulate in the blood and affect the brain, causing symptoms ranging from subtle confusion and sleep disturbances to severe disorientation or coma. The mainstay treatment is lactulose, a synthetic sugar that draws ammonia into the colon and promotes its excretion. For preventing recurrent episodes, adding rifaximin, a poorly absorbed antibiotic that alters gut bacteria, provides additional benefit. A meta-analysis of randomized trials found that the combination of rifaximin plus lactulose reduced mortality compared with lactulose alone.¹⁷ Current evidence supports using lactulose as the backbone for long-term prevention and adding rifaximin for patients who have breakthrough episodes despite lactulose therapy.¹⁸

Hepatorenal Syndrome

Hepatorenal syndrome is a form of kidney failure that occurs as a downstream effect of severe liver disease. The kidneys themselves are structurally normal; they fail because the circulatory disturbances caused by cirrhosis starve them of adequate blood flow. Treatment typically involves terlipressin, a drug that constricts splanchnic blood vessels and redirects flow to the kidneys, given alongside intravenous albumin. In a large randomized trial, roughly a third of patients treated with terlipressin achieved reversal of kidney failure, compared with about one in six who received placebo.¹⁹ Earlier studies confirmed that albumin substantially boosts the response to terlipressin.²⁰ Even with treatment, hepatorenal syndrome carries a grim prognosis and is often the trigger for urgent transplant evaluation.

Spontaneous Bacterial Peritonitis

Infection of the ascitic fluid, called spontaneous bacterial peritonitis, is treated with intravenous antibiotics, but adding intravenous albumin at the time of diagnosis reduces the risk of kidney failure and death compared with antibiotics alone.²¹ A meta-analysis of randomized trials found that albumin infusion cut mortality from about 35% to 16% in affected patients.²² The benefit appears most pronounced in higher-risk patients, particularly those with already elevated bilirubin or creatinine levels.²³

The Gut-Liver Connection

An increasingly recognized contributor to cirrhosis complications is what happens in the intestine. In cirrhosis, the gut barrier becomes more permeable, allowing bacteria and their byproducts to leak into the bloodstream, a concept often called “leaky gut.” At the same time, the balance of intestinal bacteria shifts: potentially harmful species overgrow while beneficial ones decline. This bacterial translocation fuels inflammation in the liver and elsewhere, worsening portal hypertension and driving complications like spontaneous bacterial peritonitis and hepatic encephalopathy.²⁴ This is part of why rifaximin works for encephalopathy: it reduces the bacterial load in the gut and thereby lowers the toxin burden reaching the liver. Research into probiotics, fecal microbiota transplant, and other microbiome-targeted therapies for cirrhosis is active, though none have yet become standard of care.

Liver Transplantation

When cirrhosis progresses to the point where the liver cannot sustain life, transplantation is the only definitive treatment. Patients are prioritized on the waiting list primarily by their MELD score (or MELD-Na, a sodium-adjusted version), which estimates the risk of dying within three months without a transplant. The system is designed so that the sickest patients get organs first, but it is imperfect. Certain conditions, such as primary biliary cholangitis, appear to carry higher waitlist mortality per unit increase in MELD-Na than other liver diseases like alcohol-related cirrhosis, meaning those patients may be sicker than their score suggests.²⁵ Exception points can be granted for conditions like liver cancer, where the MELD score may underestimate urgency.²⁶

Long-term survival after transplant is good but not without challenges. A study tracking recipients over two decades reported survival rates of roughly 83% at one year, 70% at five years, and 59% at ten years.²⁷ The leading causes of death shift over time. In the first year, infection and graft failure dominate. Beyond five years, new cancers (unrelated to the original liver disease) and cardiovascular disease become increasingly important causes of death.²⁸ These later risks are partly driven by the lifelong immunosuppressive drugs that transplant recipients must take. The main agents, calcineurin inhibitors like tacrolimus, are linked to kidney damage, diabetes, and metabolic syndrome over time.²⁹ The balancing act between enough immunosuppression to prevent rejection and little enough to limit side effects is a lifelong process.

Children with cirrhosis from metabolic diseases and biliary atresia can also undergo transplantation with good results. Overall survival rates in pediatric transplants for metabolic diseases and biliary atresia are similar, though the complication profiles differ. Children with metabolic diseases tend to be older at the time of transplant and may face higher rates of arterial complications, while children with biliary atresia tend to have more advanced liver failure at baseline.³⁰

Bridge Therapies and Experimental Approaches

For patients who are deteriorating rapidly while waiting for a transplant, bridge therapies aim to keep them alive and stable long enough to reach surgery. One such device is the molecular adsorbent recirculating system, or MARS, which filters toxins from the blood in a way that mimics some liver functions. MARS can improve laboratory markers of liver failure and reduce the severity of encephalopathy and kidney dysfunction.³¹ However, large controlled trials have not demonstrated improved transplant-free survival, so the current consensus is that artificial liver support devices are justified as a bridge to transplant rather than as a standalone treatment.³²

Mesenchymal stem cell therapy is an experimental approach generating considerable interest. These cells, typically derived from umbilical cord tissue, appear to modulate the immune response and reduce fibrosis progression. A systematic review and meta-analysis found that mesenchymal stem cell treatment improved liver function scores and showed protective effects against complications and liver cancer development.³³ A long-term follow-up of a randomized trial found that the survival benefit of stem cell treatment became apparent only after about 13 months, suggesting the effect takes time to materialize.³⁴ Stem cell therapy is not yet available as a standard treatment outside of clinical trials, but the early signals are encouraging enough that research is accelerating.

Monitoring Without a Needle

Tracking how cirrhosis is progressing, or whether it is responding to treatment, used to require repeated liver biopsies. While biopsy remains the gold standard for detailed tissue assessment, it is invasive and carries a small but real risk of bleeding. Elastography, which uses ultrasound or magnetic resonance imaging to measure liver stiffness, has become a practical noninvasive alternative. Liver stiffness correlates well with the degree of fibrosis, and the technique can be repeated at regular intervals without discomfort or risk.³⁵ This makes it possible to track whether treatments are working and to catch worsening fibrosis before complications develop, which directly informs decisions about escalating or changing therapy.

Palliative Care Is Not Just for the End

There is a persistent misconception that palliative care means giving up. In cirrhosis, palliative care teams focus on controlling the substantial symptom burden that accompanies advanced liver disease: pain, itching, muscle cramps, fatigue, depression, and anxiety. A study of patients with end-stage liver disease awaiting transplant found that early palliative care intervention improved both symptom burden and mood.³⁶ Palliative care runs alongside disease-modifying treatments, including transplant evaluation, not instead of them.³⁷

Timing matters for another reason: as cirrhosis worsens, hepatic encephalopathy can impair a person’s ability to make decisions about their own care. Establishing goals-of-care conversations early, while the patient can still participate fully, helps ensure their wishes are respected later.³⁸ For patients who are not transplant candidates, whether because of age, other medical conditions, or personal preference, palliative care becomes the central framework for maximizing quality of life in whatever time remains.